Hair loss biotech Veradermics, up 656% since its IPO, credits the obesity boom

Summary

Veradermics, a hair loss biotech, has surged 656% since its IPO debut with $256.3 million in proceeds and subsequent $472 million raise. CEO Reid Waldman attributes the strong post-IPO performance to leveraging obesity-related consumer-driven distribution channels.